On 18th June 2016, Celon Pharma S.A. took part in the 2nd Central European Biomedical Congress which was held in Cracow. The theme of this year's CEBC edition was “From emerging biochemical strategies to personalised medicine”.
Aleksandra Stańczak, PhD – leader of the Oncology Research Group in the Celon Pharma S.A. held a lecture entitled "Knowledge-based design of a novel selective pan-FGFR kinase inhibitor".
"We presented the CELONKO project, and with it, our innovative approach associated with the development of a personalised therapy based on a selective FGFR inhibitor" commented Aleksandra Stańczak, PhD, leader of the Oncology Research Group.
We found the event to be a great opportunity for us to present the results of our preclinical study to an international circle of experts, doctors and students of pharmacy, biology and biotechnology. "We have demonstrated that Poland, too conducts research at the highest level, of which the CELONKO project is a prime example" said Jerzy Pieczykolan, PhD, Head of the Preclinical Research Department in the Celon Pharma S.A. Research and Development Centre.
The CELONKO is co-financed from the National Centre for Research and Development and is implemented by a scientific-business consortium led by Celon Pharma along with the National Research Institute for Tuberculosis and Lung Diseases in Warsaw, the Military Institute of Medicine in Warsaw, the Maria Skłodowska-Curie Institute of Oncology in Warsaw and the Medical University of Gdańsk.
CEBC was organised by: The Institute of Pharmacology of the Polish Academy of Sciences (Cracow) and the Faculty of Medicine of the Jagiellonian University Medical College. The event enjoyed the honorary patronage of His Magnificence Rector of Faculty of the Jagiellonian University, Prof. Wojciech Nowak, PhD and President of the Polish Academy of Sciences, Prof. Jerzy Duszyński, PhD.